세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 보고서(2025년)

Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Global Market Report 2025

US $ 4,490 ￦ 6,231,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,006,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,782,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 2029년에는 연평균 성장률(CAGR) 6.0%로 32 억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 주사제보다 경구 요법에 대한 수요가 증가하고,자가 면역 질환의 유병률이 증가하고, 세계 건강 관리 지출이 증가하고, 다발 성경화증 등의 질병에 대한 인식과 진단의 높아짐, 자가면역질환에 걸리기 쉬운 노년 인구 증가 등에 기인한다고 생각됩니다.

자가면역 질환의 유병률 증가는 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장의 확대를 촉진할 것으로 예측됩니다. 진단 능력의 향상 등의 요인이 이러한 질병의 발생률 증가에 기여하고 있습니다. Center for Health Statistics(NCHS)가 발표한 데이터에 따르면 미국의 18세 이상의 성인에서 현재 천식 유병률은 2021년 8.4%에서 2022년 8.7%로 증가했습니다. 지난 12개월 이내 천식 에피소드의 발생률은 2021년의 3.3%에서 2022년에는 3.7%로 상승했습니다.

스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장의 주요 기업은 환자의 컴플라이언스를 개선하고, 약효를 높이고, 자가면역 질환 관리에서 이러한 약물의 치료 가능성을 확대하기 위해 경구 치료와 같은 혁신적인 치료법의 개발을 중시하고 있습니다. 예를 들어, 2022년 3월 미국 제약 및 생명공학 기업인 화이자는 궤양성 대장염 환자를 대상으로 한 에트라 시모드의 3상 임상시험의 양호한 결과를 발표했습니다. 화염에 대한 새로운 치료 옵션으로서의 에트라시모드의 잠재력을 강조하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 성장률 분석
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 실적 : 규모와 성장, 2019-2024
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 핑고리모드
• 오자니모드
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 오랄
• 주사제
• 주제
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 다발성 경화증
• 심혈관 질환
• 이식거절반응
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 재활센터
• 소매 약국
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 핑고리모드유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 브랜드 처방
• 제네릭 의약품
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 오자니모드유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구 캡슐
• 기타 처방

제7장 지역별/국가별 분석

• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 경쟁 구도
• 스핑고신 1 인산 수용체(S1PR) 모듈레이터 의약품 시장 : 기업 프로파일
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Novartis International AG
• Biogen Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ono Pharmaceutical Co. Ltd.
• Actelion Pharmaceuticals Ltd.
• KYORIN Pharmaceutical Co. Ltd.
• Vanda Pharmaceuticals Inc.
• Celgene Corporation
• Ventyx Biosciences Inc.
• Idorsia Pharmaceuticals Ltd.
• Cayman Chemical Company
• Juvise Pharmaceuticals
• Priothera Limited
• Arena Pharmaceuticals

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 스핑고신 1인산 수용체(S1PR) 모듈레이터 의약품 시장(2029년) : 새로운 기회를 제공하는 국가
• 스핑고신 1인산 수용체(S1PR) 모듈레이터 의약품 시장(2029년) : 새로운 기회를 제공하는 부문
• 스핑고신 1인산 수용체(S1PR) 모듈레이터 의약품 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Sphingosine 1 phosphate receptor (S1PR) modulator drugs are a class of therapeutic agents that specifically target sphingosine-1-phosphate (S1P) receptors, a family of G-protein-coupled receptors involved in essential cellular processes. These drugs regulate the activity of S1P receptors, which play a crucial role in immune cell trafficking, vascular function, and inflammation.

The primary types of sphingosine 1 phosphate receptor (S1PR) modulator drugs include fingolimod and ozanimod. Fingolimod is an oral medication used for treating multiple sclerosis (MS) by modulating the immune system to prevent nerve damage associated with the disease. These drugs are available in different routes of administration, including oral, injectable, and topical forms, and are used for treating multiple sclerosis, cardiovascular diseases, and transplant rejection. Their primary end-users include hospitals, rehabilitation centers, and retail pharmacies.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report is one of a series of new reports from The Business Research Company that provides sphingosine 1 phosphate receptor (S1PR) modulator drugs market statistics, including the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry global market size, regional shares, competitors with the sphingosine 1 phosphate receptor (S1PR) modulator drugs market share, detailed sphingosine 1 phosphate receptor (S1PR) modulator drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry. This sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size has grown strongly in recent years. It will grow from $2.44 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to the increasing prevalence of autoimmune diseases, greater investment in autoimmune drug development, the expansion of treatment indications, rising awareness of autoimmune disease management, and higher healthcare expenditure.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size is expected to see strong growth in the next few years. It will grow to $3.28 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing demand for oral therapies over injectables, increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, growth in awareness and diagnosis of conditions such as multiple sclerosis, and rising geriatric population prone to autoimmune diseases. Major trends in the forecast period include advancements in receptor selectivity, regulatory approvals for new indications, integration of real-world evidence (RWE), technological advancements in drug delivery, a shift toward oral therapies, strategic collaborations, and acquisitions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, leading to inflammation and tissue damage. Factors such as genetics, environmental triggers, lifestyle changes, and improved diagnostic capabilities contribute to the growing incidence of these conditions. S1PR modulator drugs help regulate immune cell migration, reducing inflammation in autoimmune diseases such as multiple sclerosis and ulcerative colitis. For example, in May 2024, data published by the National Center for Health Statistics (NCHS), a US-based health statistics agency, indicated that the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes within the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. As a result, the rising prevalence of autoimmune diseases is fueling the growth of the S1PR modulator drugs market.

Leading companies in the S1PR modulator drugs market are emphasizing the development of innovative therapies, such as oral treatments, to improve patient compliance, enhance drug efficacy, and expand the therapeutic potential of these medications in managing autoimmune diseases. Oral therapy involves administering medications in pill or tablet form, providing a convenient and non-invasive treatment option for patients. For instance, in March 2022, Pfizer, a US-based pharmaceutical and biotechnology company, announced positive phase 3 trial results for etrasimod in ulcerative colitis patients. The drug met its primary and key secondary endpoints, demonstrating significant improvements in remission rates, endoscopic outcomes, and symptom relief. These results highlight etrasimod's potential as a new treatment option for moderate-to-severe ulcerative colitis. Pfizer plans to advance regulatory submissions, reinforcing its immuno-inflammatory disease portfolio and commitment to innovative healthcare solutions.

In December 2023, Vanda Pharmaceuticals, a US-based pharmaceutical company, acquired the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition strengthens Vanda's portfolio by adding an innovative therapy for relapsing multiple sclerosis (MS), a condition with increasing prevalence and a significant unmet medical need. Actelion Pharmaceuticals Ltd., a Switzerland-based biopharmaceutical company, specializes in developing sphingosine 1-phosphate receptor (S1PR) modulator drugs for various diseases.

Major players in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvise Pharmaceuticals, Priothera Limited, and Arena Pharmaceuticals.

Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PT) modulator drugs market in 2024. The regions covered in sphingosine 1 phosphate receptor (S1PR) modulator drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market consists of sales of non-selective S1PR modulators, selective S1PR1 modulators, and next-generation and experimental S1PR modulators. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sphingosine 1 phosphate receptor (s1pr) modulator drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sphingosine 1 phosphate receptor (s1pr) modulator drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sphingosine 1 phosphate receptor (s1pr) modulator drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Fingolimod; Ozanimod
• 2) By Route Of Administration: Oral; Injectable; Topical
• 3) By Application: Multiple Sclerosis; Cardiovascular Diseases; Transplant Rejection
• 4) By End User: Hospital; Rehabilitation Centres; Retail Pharmacies
• Subsegments:
• 1) By Fingolimod: Branded Formulations; Generic Formulations
• 2) By Ozanimod: Oral Capsules; Other Formulations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Characteristics

3. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Trends And Strategies

4. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Growth Rate Analysis
• 5.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Total Addressable Market (TAM)

6. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Segmentation

• 6.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fingolimod
• Ozanimod
• 6.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Sclerosis
• Cardiovascular Diseases
• Transplant Rejection
• 6.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Rehabilitation Centres
• Retail Pharmacies
• 6.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Fingolimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Formulations
• Generic Formulations
• 6.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Ozanimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Capsules
• Other Formulations

7. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Regional And Country Analysis

• 7.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 8.1. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 9.1. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 9.2. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 10.1. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 11.1. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 11.2. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 12.1. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 13.1. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 14.1. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 14.2. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 15.1. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 15.2. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 16.1. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 17.1. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 18.1. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 19.1. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 20.1. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 21.1. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 21.2. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 22.1. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 23.1. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 23.2. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 24.1. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 24.2. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 25.1. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 25.2. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 26.1. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 26.2. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 27.1. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 28.1. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 28.2. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 29.1. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 29.2. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape And Company Profiles

• 30.1. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape
• 30.2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Biogen Inc.
• 31.3. Eisai Co. Ltd.
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. Ono Pharmaceutical Co. Ltd.
• 31.6. Actelion Pharmaceuticals Ltd.
• 31.7. KYORIN Pharmaceutical Co. Ltd.
• 31.8. Vanda Pharmaceuticals Inc.
• 31.9. Celgene Corporation
• 31.10. Ventyx Biosciences Inc.
• 31.11. Idorsia Pharmaceuticals Ltd.
• 31.12. Cayman Chemical Company
• 31.13. Juvise Pharmaceuticals
• 31.14. Priothera Limited
• 31.15. Arena Pharmaceuticals

32. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

34. Recent Developments In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

35. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료